Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
Oct 17 (Reuters) - Rani Therapeutics RANI.O said on Friday it has agreed a deal to license an oral drug to Japan's Chugai Pharmaceutical 4519.T, with an option to extend it to up to five drugs, potentially bringing the total deal value to $1.09 billion. (Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition